PellePharm
PrivateLast Round
Series C
Nov 20, 2018
Total Funding Raised
$94.5M
Company Overview
PellePharm operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Series C round in November 2018.
PellePharm is a biotechnology company that develops precision medicine therapies for rare dermatological conditions, including Gorlin Syndrome and Basal Cell Carcinomas.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PellePharm Comparables
Compare PellePharm with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| DermBiont | 86% | |
| Sol-Gel Technologies Ltd. | 83% | |
| Inhibitor Therapeutics, Inc. | 81% |
For institutional investors. Book with your work email.
PellePharm Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Nov 20, 2018 | ||||
| Series B | Jul 31, 2017 | ||||
| Series A | Jul 1, 2015 |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 31, 2017
$20M round led by BridgeBio Pharma
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- sells_assets_toOct 14, 2026
PellePharm, Inc. sells an asset to Sol-Gel Technologies Ltd., which conducts a new Phase III study after the prior trial does not achieve expected statistical significance.
For institutional investors. Book with your work email.
PellePharm Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about PellePharm's valuation, stock price, and market status.
Is PellePharm a public or private company?
PellePharm is a private company.
What is the current stock price of PellePharm?
PellePharm is a private company, so its shares have no public market price. Caplight tracks PellePharm's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is PellePharm worth (valuation)?
Valuation information for PellePharm is not publicly available.
Can I buy PellePharm stock?
PellePharm shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was PellePharm's last funding round?
PellePharm's most recent funding round was Series C on November 20, 2018.
Who are the main investors in PellePharm?
Investor information for PellePharm is not publicly disclosed.
Will PellePharm IPO soon?
No public IPO plans have been announced for PellePharm.
How can I track PellePharm secondary market activity?
Caplight tracks bids, offers, and trades in PellePharm's shares on secondary markets.